@article{81546d3bf1a340ea9f1175b752f33abd,
title = "The Role of Trimethoprim/Sulfamethoxazole in the Treatment of Infections Caused by Carbapenem-Resistant Enterobacteriaceae",
abstract = "In the Consortium on Resistance Against Carbapenems in Klebsiella and other Enterobacteriaceae (CRACKLE), trimethoprim-sulfamethoxazole (TMP-SMX) had a limited role in the treatment of less severe carbapenem-resistant Enterobacteriaceae (CRE) infections, especially urinary tract infections. Of tested CRE, only 29% were susceptible to TMPSMX. Development of resistance further limits the use of TMPSMX in CRE infections.",
author = "Luterbach, {Courtney L.} and Ashley Boshe and Henderson, {Heather I.} and Eric Cober and Richter, {Sandra S.} and Salata, {Robert A.} and Kalayjian, {Robert C.} and Watkins, {Richard R.} and Hujer, {Andrea M.} and Hujer, {Kristine M.} and Rudin, {Susan D.} and Domitrovic, {T. Nicholas} and Yohei Doi and Kaye, {Keith S.} and Scott Evans and Fowler, {Vance G.} and Bonomo, {Robert A.} and {Van Duin}, David",
note = "Funding Information: Potential conflicts of interest. S.S.R: research support from bio-Merieux, BD Diagnostics, Roche, Hologic, Diasorin. Y.D.: grant support from Accelerate Diagnostics, NIH; advisory board: Tetraphase, Roche, Geom. K.K: consultant, grant investigator, speaker{\textquoteright}s bureau, consulting fee, grant recipient, and speaker honorarium from Allergan; grant recipient, consultant for Merck; consultant for Xellia; consultant for Achaogen. R.R.W.: grant support from Allergan. R.A.B.: grant/research support from Achaogen, Allecra, Entasis, Merck, Roche, Shionogi, Wockhardt. V.G.F.: grant/research support from Advanced Liquid Logic, Cubist, Cerexa, MedImmune, Merck, NIH, Novartis, Pfizer, Theravance; paid consultant for Affinium, Baxter, Cerexa, Cubist, Debiopharm, Durata, Merck, Novartis, NovaDigm, The Medicines Company, MedImmune, Pfizer, Theravance, Trius; honoraria from Arpida, Astellas, Cubist, Inhibitex, Merck, Pfizer, Targanta, Theravance, Wyeth, Ortho-McNeil, Novartis, Vertex Pharmaceuticals; memberships in Merck Co-Chair V710 Vaccine. D.v.D.: advisory board for Actavis, Tetraphase, Sanofi-Pasteur, MedImmune, Astellas, Merck, Allergan, T2Biosystems, Roche, Achaogen, Neumedicine, Shionogi. Research funding from Scynexis and Steris Inc. No conflicts of interest: C.L.L., A.B., H.I.H., E.C., R.A.S., R.C.K., A.M.H., K.M.H., S.D.R., T.N.D., and S.E. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. Funding Information: Financial support. This work was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH) under award numbers UM1AI104681 and R21AI114508, by funding to D.V.D. and F.P. from the Clinical and Translational Science Collaborative of Cleveland, and by award number UL1TR000439 from the National Center for Advancing Translational Sciences (NCATS) component of the NIH and NIH roadmap for Medical Research. V.G.F. was supported by the Mid-Career Mentoring Award K24-AI093969 from the NIH. In addition, research reported in this publication was supported in part by the National Institute of Allergy and Infectious Diseases of the NIH under award numbers R21AI114508 (D.v.D. and R.A.B.), R01AI100560 (R.A.B.), R01AI063517 (R.A.B.), and R01AI072219 (R.A.B.). This study was supported in part by funds and/or facilities provided by the Cleveland Department of Veterans Affairs, award number 1I01BX001974 to R.A.B. from the Biomedical Laboratory Research & Development Service of the VA Office of Research and Development, and the Geriatric Research Education and Clinical Center VISN 10 (R.A.B.). Further support came from the Research Program Committees of the Cleveland Clinic (D.V.D.) and an unrestricted research grant from the STERIS Corporation (D.V.D.). Y.D. was supported by research awards R01AI104895, R21AI123747, and R21AI135522 from the NIH. K.S.K. was supported by the National Institute of Allergy and Infectious Diseases (Division of Microbiology and Infectious Diseases protocol 10–0065 and R01AI119446-01). Funding Information: This work was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH) under award numbers UM1AI104681 and R21AI114508, by funding to D.V.D. and F.P. from the Clinical and Translational Science Collaborative of Cleveland, and by award number UL1TR000439 from the National Center for Advancing Translational Sciences (NCATS) component of the NIH and NIH roadmap for Medical Research. V.G.F. was supported by the Mid-Career Mentoring Award K24-AI093969 from the NIH. In addition, research reported in this publication was supported in part by the National Institute of Allergy and Infectious Diseases of the NIH under award numbers R21AI114508 (D.v.D. and R.A.B.), R01AI100560 (R.A.B.), R01AI063517 (R.A.B.), and R01AI072219 (R.A.B.). This study was supported in part by funds and/or facilities provided by the Cleveland Department of Veterans Affairs, award number 1I01BX001974 to R.A.B. from the Biomedical Laboratory Research & Development Service of the VA Office of Research and Development, and the Geriatric Research Education and Clinical Center VISN 10 (R.A.B.). Further support came from the Research Program Committees of the Cleveland Clinic (D.V.D.) and an unrestricted research grant from the STERIS Corporation (D.V.D.). Y.D. was supported by research awards R01AI104895, R21AI123747, and R21AI135522 from the NIH. K.S.K. was supported by the National Institute of Allergy and Infectious Diseases (Division of Microbiology and Infectious Diseases protocol 10-0065 and R01AI119446-01). Publisher Copyright: {\textcopyright} The Author(s) 2018.",
year = "2019",
month = jan,
day = "1",
doi = "10.1093/ofid/ofy351",
language = "English",
volume = "6",
journal = "Open Forum Infectious Diseases",
issn = "2328-8957",
publisher = "Oxford University Press",
number = "1",
}